

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

RE-DESIGNATION OF DIRECTOR

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Reference is also made to the overseas regulatory announcement dated 3 September 2023.

Dr. Feng Hui (“**Dr. Feng**”) tendered his resignation from the position of chief operations officer and all other positions in the subsidiaries of the Company with effect from 31 August 2023 due to personal reasons. Following his resignation from the aforesaid positions, Dr. Feng has been re-designated as a non-executive director of the Company (“**Director**”) from his previous role as an executive Director (the “**Re-designation**”).

The biographical information of Dr. Feng is as follows:

Dr. Feng was appointed as an executive Director in March 2015, and had served as the chief operations officer of TopAlliance Biosciences Inc. since January 2014, the executive director and legal representative of Shanghai Junshi Biotechnology Co., Ltd.* (上海君實生物工程有限公同) since June 2016, and the executive director and general manager of Suzhou Junmeng Biosciences Co., Ltd.* (蘇州君盟生物醫藥科技有限公同) since August 2017.

Dr. Feng took part in the invention of certain registered patents and patents in application in relation to JS001, JS002 and JS004 for our Group. Dr. Feng’s main experience prior to joining our Group includes: from 2003 to 2007, he worked at Albert Einstein College of Medicine; from 2007 to 2010, he was a production manager in Human Zyme Inc.; from September 2010 to November 2013, he was a scientist in MedImmune, Inc. (a subsidiary of AstraZeneca).

Dr. Feng obtained his bachelor’s degree in biological sciences and technology from Tsinghua University, PRC in July 1997 and his Ph.D. degree in molecular pharmacology from Albert Einstein College of Medicine, the United States in September 2003.

In respect of the Re-designation, Dr. Feng has entered into a new service contract with the Company for a term commencing on 31 August 2023 and expiring on the conclusion of the third session of the board of directors of the Company (the “**Board**”). His term of office is determinable by either party serving on the other not less than three months’ written notice, and subject to retirement by rotation and re-appointment in accordance with the Company’s Articles of Association and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The remuneration of Dr, Feng will be determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee of the Company from time to time. Dr. Feng has not entered into nor proposed to enter into any service contracts, which fall within the meanings of Rule 13.68 of the Listing Rules requiring the prior approval of shareholders of the Company (the “**Shareholders**”) at general meetings, with the Company.

As at the date of this announcement, Dr. Feng is deemed to be interested in 13,652,000 A shares of the Company (“**A Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing 1.78% and 1.39% of the total number of issued A Shares and issued share capital of the Company, respectively. 13,180,000 A Shares out of the 13,652,000 A Shares are directly held by Dr. Feng. He was granted 820,000 restricted A Shares on 16 November 2020 under the 2020 Restricted A Share Incentive Scheme adopted by the Company on 16 November 2020. He received a total of 40,000 A Shares as a result of the attribution of the first grant under the 2020 Restricted A Share Incentive Scheme on 1 November 2022 and 2 February 2023. 308,000 restricted A Shares out of the 820,000 restricted A Shares have been nullified on 16 November 2022. Hence Dr. Feng remains to be interested in 472,000 restricted A Shares.

As at the date of this announcement, save as disclosed above, Dr. Feng has confirmed that he: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did he hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters concerning the Re-designation that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Re-designation is not expected to have any substantive impact to the Company’s research & development, its operation, core technology and competitiveness. Mr. Zhang Zhuobing and Dr. Yao Sheng, both being executive Directors, have taken on Dr. Feng’s existing responsibilities prior to the Re-designation. The Company will engage Dr. Feng as a technical consultant following the Re-designation to enable the smooth transition of relevant research and development work. Dr. Feng has confirmed that he has no disagreement with the Board and there are no other matters that should be brought to the attention of the Shareholders in relation to his resignation from the above-mentioned positions.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Feng for his contributions to the Company during his tenure of office as an executive Director and extend its warmest welcome to Dr. Feng in serving his new position as a non-executive Director.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 3 September 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Feng Hui and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*